
23andMe Inc - Strategic SWOT Spotlight
Description
23andMe Inc - Strategic SWOT Spotlight
23andMe Inc - Strategic SWOT Spotlight is a comprehensive and easily accessible overview of The 23andMe Inc's business operations. It provides a Snapshot of the company's position in the industry compared to competitors. The report includs key executives, products and services, ESG spotlight, Corporate Strategy, Business Description, Helicopter view of SWOT Analysis, Competitive Landscape and latest events.
Key Highlights
23andMe Inc is a personal genomics and biotechnology company that operates as a direct-to-consumer genetic testing and research company. They offer a variety of products and services related to genetic testing and analysis. Their main offering is the 23andMe DNA test, which provides customers with information about their ancestry, health, and traits based on their genetic data. They also offer a Health + Ancestry Service, which includes additional health-related reports and features. In addition, 23andMe offers a DNA Relatives feature, which allows customers to connect with and potentially discover relatives based on shared DNA. The company also conducts genetic research and offers customers the opportunity to participate in research studies. Overall, 23andMe provides individuals with personalized and in-depth insights into their genetic makeup and ancestry. Founded in 2006, the company is headquartered in San Francisco, California, United States.
23andMe Inc in the News:-
- 05-Jun-2024 - 23andMe Launches New Genetic Report on Bipolar Disorder
- 04-Jun-2024 - 23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
- 03-Jun-2024 - 23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
- 29-May-2024 - Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
- 23-May-2024 - 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Company Fundamentals:- These fundamentals offer valuable insights into 23andMe Inc's operations, geographical presence, products and services, ESG spotlight, Corporate Strategy, Business Description and SWOT spotlight, aiding in a comprehensive understanding of the organization.
Reasons to Buy
- Helicopter view of company's internal and external factors through SWOT analysis - Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers. - Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations. - Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Table of Contents
47 Pages
- Table of Contents
- Tables
- Charts
- 23andMe Inc - Key Company Facts
- 23andMe Inc - Company Description
- 23andMe Inc - Head Office & Locations
- Head Office - Country
- 23andMe Inc - Products and Services
- Products
- Services
- 23andMe Inc - Corporate Strategy
- 23andMe Inc - Business Description
- Consumer & Research Services
- Therapeutics
- 23andMe Inc - ESG Spotlight
- Environment
- Social
- Corporate Governance
- 23andMe Inc - SWOT Spotlight
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Competing Players
- Snapshot of Competing Players
- Genetic Technologies Ltd
- Key Company Facts
- Company Description
- Key Financials:
- MyHeritage Ltd
- Key Company Facts
- Company Description
- Veritas Intercontinental SL
- Key Company Facts
- Company Description
- Color Health, Inc.
- Key Company Facts
- Company Description
- 23andMe Inc - In the News 05-Jun-2024- 23andMe Launches New Genetic Report on Bipolar Disorder 04-Jun-2024- 23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community 03-Jun-2024- 23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
- 29-May-2024- Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
- 23-May-2024- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
- Appendix
- Definitions
- SWOT Analysis
- PESTLE Analysis
- Value Chain Analysis
- ESG Spotlight
- Research Methodology
- Disclaimer
- Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.